As you may know, abstracts will not be released until May 18th at 6pm ET. However presentation titles are available. Here are the presentations related to SNTA's HSP90 inhibitor ganetespib:
Saturday June 4th: Oral Presentation [this is the most significant one for SNTA stock]
Abstract #7500 8:00 AM - 8:15 AM
"An open-label phase II study of the Hsp90 inhibitor ganetespib (STA-9090) as monotherapy in patients with advanced non-small cell lung cancer (NSCLC)."
Kwok-Kin Wong, MD
Saturday June 4th: Poster Presentation
Abstract #10011
"An open-label phase II study of the Hsp90 inhibitor ganetespib (STA-9090) in patients (pts) with metastatic and/or unresectable GIST."
George D. Demetri, MD
Monday June 6th: Poster Presentation
Abstract #3051
"A phase I dose-escalation study of the Hsp90 inhibitor ganetespib (STA-9090) administered twice weekly in patients with solid tumors: Updated report."
Daniel C. Cho, MD
Saturday June 4th: Oral Presentation [this is the most significant one for SNTA stock]
Abstract #7500 8:00 AM - 8:15 AM
"An open-label phase II study of the Hsp90 inhibitor ganetespib (STA-9090) as monotherapy in patients with advanced non-small cell lung cancer (NSCLC)."
Kwok-Kin Wong, MD
Saturday June 4th: Poster Presentation
Abstract #10011
"An open-label phase II study of the Hsp90 inhibitor ganetespib (STA-9090) in patients (pts) with metastatic and/or unresectable GIST."
George D. Demetri, MD
Monday June 6th: Poster Presentation
Abstract #3051
"A phase I dose-escalation study of the Hsp90 inhibitor ganetespib (STA-9090) administered twice weekly in patients with solid tumors: Updated report."
Daniel C. Cho, MD
RSS Feed
